EXCLUSIVE: The White House is expecting to announce an expansion of drugmakers offering discounts on TrumpRx.gov, FOX Business has learned. As early as today, Amgen and GSK will be added to the list ...

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

Great. Thank you for coming, everybody. I'm James Gordon, Barclays European pharma and biotech analyst. And today, I've got the pleasure of hosting a fireside with GSK. So we're going to hear from GSK ...

As Congress mulls whether to follow President Donald Trump’s orders for a most-favored-nation drug-pricing policy, biotech firm executives are starting to speak out against the measure.

GSK and Alfasigma have signed a licensing agreement granting Alfasigma worldwide exclusive rights to develop, manufacture and commercialise linerixibat, an investigational IBAT inhibitor for the ...

Speaking at a recent meeting of the British Pharmacological Society in Brighton, UK, Christine Mummery described how using embryonic stem cells to create human heart cells could b ...

Debevoise & Plimpton LLP announced the launch of STAAR 2.0, an enhanced version of its award-winning* client-facing AI platform designed to help in-house legal and compliance teams evaluate, govern, ...

GSK Plc agreed to buy 35Pharma Inc., a biotech with an early-stage drug for pulmonary hypertension, as the UK pharma giant boosts its pipeline of promising experimental therapies. GSK will buy the ...

GSK struck a $950 million deal to buy Canada’s 35Pharma, a biopharmaceutical company developing cardiopulmonary treatments, as the U.K. drugmaker seeks to bolster its exposure to diseases linked to ...

Frontier Biotechnologies Inc. has entered into an exclusive licensing agreement with GSK plc whereby GSK will obtain exclusive worldwide rights to develop, manufacture and commercialize two of ...

Feb 24 - Frontier Biotechnologies (688221.SS), opens new tab said on Tuesday it has struck a deal with GSK (GSK.L), opens new tab, granting the British drugmaker worldwide rights to develop two small ...

By integrating GSK's deep knowledge of neurodegeneration, translational science and drug discovery with JAX-NYSCF's pioneering stem cell technology and expertise, access to relevant patient cohorts, ...